Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation concerning potential securities fraud or unlawful business practices. The investigation follows a June 26, 2026 announcement that the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a negative opinion on Omeros's marketing authorization application for narsoplimab in treating hematopoietic stem cell transplant-associated thrombotic microangiopathy. On that news, Omeros's stock price fell $2.05 per share, or 19.12%, to close at $8.67 per share. Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, extension 7980.
Omeros CorporationEuropean Medicines Agency committee adopted negative opinion on narsoplimab marketing authorization application.